

## **COVID-19 Research Overview**

### **RECOVERY – Randomised Evolution of COVID-19 Therapy – Open to Recruitment**

#### **Status – Open to Recruitment**

The RECOVERY Trial is testing suggested treatments on COVID19+ patients

Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients.

The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.

**Total Recruited - 334**

### **ISARIC - Clinical Characterisation Protocol for Severe Emerging Infection**

#### **Status – Open to Recruitment**

This study will gain important information about COVID-19 in order to try to find better ways to manage and treat the infection in the future.

Information is collected from routine clinical records such as signs and symptoms, medications being taken, and the results of any blood test and laboratory results that doctors have ordered in hospital.

Samples may be collected which are in addition to what would normally be collected for your medical care, if recruited to Tier 2

We have recently been notified that the data from this study informs vaccines.

**Total Recruited – 509**

### **PHOSP-COVID – New Study**

#### **Status – Open to Recruitment**

A national consortium to understand and improve long-term health outcomes

All patients who are admitted to UK recruiting hospital sites will be invited to join the study following discharge from hospital with clinician suspected COVID-19

**Total Recruited – 45**

## GENOMICC - Genetics of susceptibility and mortality in critical care

### **Status – Open to Recruitment**

Susceptibility to COVID-19 is almost certainly, in part, genetic.

GenOMICC can find the genes that cause susceptibility, which may help to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis.

All patients with confirmed COVID-19 in Critical Care are eligible for GenOMICC.

**Total Recruited – 32**

## REMAP-CAP – Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia

### **Status – Open to Recruitment**

A trial designed by clinicians who cared for patients and conducted research during the 2009 H1N1 pandemic.

The goal is to generate evidence that can be applied during the pandemic to reduce mortality or reduce the length of ICU admission in critically ill patients with COVID-19 infection.

**Total Recruited – 3**

## Psychological Impact of COVID-19 - The psychological impact of surviving an intensive care admission due to COVID-19

### **Status – Open to Recruitment**

To identify the proportion of patients surviving an admission to intensive care due to COVID-19 who experience anxiety, depression and/or trauma symptoms in the 6 months post-discharge, assessed using the Hospital Anxiety and Depression Scale (HADS) and the Impact of Event Scale-6 (IES-6). We will attempt to identify demographic, clinical and/or psychosocial predictors of depression, anxiety and/or trauma symptoms at 3-, 6- and 12-months post discharge from ICU.

**Total Recruited – 20**

## COVIDTrach; a UK national cohort study of mechanically ventilated COVID-19 patients undergoing tracheostomy

### **Status – Open to Recruitment**

COVIDTrach is collaborative project by surgeons and intensive care doctors that looks at the outcomes of ventilated COVID-19 patients undergoing tracheostomy and evaluates the use of personal protective equipment and rate of COVID-19 infection amongst operators.

**Total Recruited – 19**

### SIREN - SARS-COV2 Immunity and Reinfection Evaluation

#### **Status – In Follow Up**

This study aims to find out whether healthcare workers who have evidence of prior COVID-19, detected by antibody assays (positive antibody tests), compared to those who do not have evidence of infection (negative antibody tests) are protected from future episodes of infection.

Healthcare workers will be followed for a set amount of time to study their immune response to the virus causing COVID-19.

All NHS staff who delivers care to patients will be asked to have a nose and throat swab every other week in order to detect mild cases or cases that do not have symptoms.

**Total Recruited – 745**

### PAN-COVID - Pregnancy and Neonatal Outcomes in COVID-19

#### **Status – In Follow Up**

PAN-COVID will develop a global database detailing a number of outcomes (death of the baby or mother, stillbirth, miscarriage, pregnancy complications, gestational age at delivery, delivery method and testing the baby for SARS-CoV-2).

The aim of this database is to understand the natural history of SARS-CoV-2 and COVID-19 and the impact on mothers and their babies to guide both treatment and prevention.

**Total Recruited – 31**

### CLARITY: Impact of Biologic Therapy on SARS-COV-2 Infection & immunity

#### **Status – In Follow Up**

This study will provide an evidence base for safer prescribing of immunomodulator and biologic drugs in the COVID-19 era and inform public health policy regarding physical distancing measures, and future vaccination strategies.

Although this study will define risk in IBD patients, there are potentially important lessons to be learned for millions of patients across the UK with other immune mediated diseases treated with similar therapies.

**Total Recruited – 100**

## PSYCHOLOGICAL IMPACT OF COVID-19 - pandemic and experience: An international survey

### **Status - Phase 3 in the pipeline**

This study will explore the psychological impact of the COVID-19 outbreak and the resultant restrictions in terms of behavioural, emotional and social factors.

Questions will be asked of the data collected to see what factors may be supportive or more detrimental to wellbeing.

The general public including health professionals and those with pre-existing mental health conditions will be invited to complete the survey.

This study is in its second wave of recruitment and has adapted its survey based on results from the first wave.

**Total Recruited – 712**

**Total – 2993 participants recruited to COVID-19 Research**

**Data cut from 1<sup>st</sup> participant recruited onto COVID-19 Research at SFH 17/03/2020 to 23/06/2021**